Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | ITGA9 |
| Gene Name: | ITGA9 |
| Protein Full Name: | Integrin alpha-9 |
| Alias: | Integrin alpha-RLC |
| Mass (Da): | 114489 |
| Number AA: | 1035 |
| UniProt ID: | Q13797 |
| Locus ID: | 3680 |
| COSMIC ID: | ITGA9 |
| Gene location on chromosome: | 3p21.3; 3p22.2 |
| Cancer protein type: | UNCLEAR |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | UNCLEAR |
| Number of cancer specimens: | 19780 |
| Percent of cancer specimens with mutations: | 0.79 |
| Normal role description: | ITGA9 is a member of the integrin family of integral membrane glycoproteins. When ITGA9 is complexed with a beta-subunit it functions as a receptor for for VCAM1, cytotactin and osteopontin. Ligands which bind ITGA9 are involved in cell adhesion and migration. ITGA9 may contribute to metastasis of tumours. Abberant expression of ITGA9 has been observed in lung cancer cell. Overexpression was observed in small cell lung cancer while homozygous deletions of the ITGA9 locus was observed in lung cancer cell lines. ITGA9's role in cancer development is still enigmatic. |